Full text is available at the source.
Abstract
The influence of frailty on the benefit-risk balance of glucagon-like peptide-1 receptor agonists (GLP-1 RA) is uncertain.
- Frailty may affect how patients respond to GLP-1 RA treatment.
- The benefit-risk balance of GLP-1 RAs is not clearly established in frail individuals.
- Further investigation is needed to understand the implications of frailty in this context.
Simplified